Plain-English translation of NCT06463847 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase I trial testing —stem cells derived from umbilical cord tissue—as a potential treatment for knee osteoarthritis. Researchers will inject these cells directly into the affected knee joint to see if they can reduce inflammation, repair damaged cartilage, and relieve pain. The study will test three different doses to find the safest and most effective amount.
Knee osteoarthritis affects over a billion people worldwide and currently has no cure—existing treatments only manage pain temporarily. This medication works differently: stem cells can reduce inflammation and potentially help your body regenerate damaged joint tissue, offering hope for a longer-lasting solution.
You likely qualify if…
You likely don't qualify if…
If enrolled, you will receive one injection of stem cells directly into your knee joint as an outpatient procedure, combined with your standard pain management. You will be assigned to one of three dose groups. You will need to stop certain pain medications before treatment and attend follow-up visits so researchers can monitor how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China